Clinical Trial Update: Study of Lenalidomide(Revlimid) Plus Rituximab (Revlirit Regimen) in Elderly Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) [Phase 2]

View source ↗

Summary

Phase 2 study evaluating lenalidomide plus rituximab (Revlirit Regimen) in elderly patients with relapsed/refractory Diffuse large B-cell lymphoma. The trial st…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Revlimid (lenalidomide)
• Rituxan (rituximab)

Snippet

Sponsor: University of Bologna | Conditions: Diffuse Large B-cell Lymphoma | Phase 2 | Status: TERMINATED